Abstract: One or more video gateway devices configured to: access pre-configured criteria including at least a first condition, a second condition, and a first event; access video content captured by cameras configured to capture video of areas of a manufacturing facility; determine, based on an analysis of the video content, that the first condition is satisfied; access sensor data from one or more sensors; determine, based on an analysis of the sensor data, that the second condition is satisfied; and based on determining that the first and second conditions are satisfied, cause the first event to be executed.

Abstract: A data analysis system for measuring a materiality feature of interest is disclosed. The system includes a computing cluster ingesting content comprising a plurality of observables relevant to an entity, wherein each observable is related to at least one feature of interest. The system further includes an extraction engine running on the computing cluster and tagging the observables with an entity identifier in response to the observables referencing at least one of an entity, a tradename associated with the entity, or product associated with the entity. Additionally, the system includes an analysis engine running on the computing cluster and tagging an observable in response to the feature of interest being related to the observable. In one embedment, the analysis engine measures the materiality of the feature of interest to the entity by counting a number of observables from the plurality of observables tagged with the entity identifier.

Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).

Abstract: A power semiconductor component for voltage limiting includes a rear-side base zone electrically contacted with a rear-side electrode and a front-side base zone electrically contacted with a front-side electrode. At least one switch-on structure is embedded at least into one of the rear-side base zone and the front-side base zone and is electrically contacted by the electrode contacting the embedding base zone. At least one triggering structure is provided as a breakdown structure of a first type, present between the front-side and rear-side electrodes. At least one further triggering structure is provided as a breakdown structure of a second type, present between the front-side and rear-side electrodes. The front-side and rear-side electrodes are each electrically conductively pressure-contacted by an electrically conductive contact plate at least one of which functions as a heat sink for dissipating heat generated in the semiconductor body.

Abstract: A hand held spray dispenser in which air and liquid are pressurised towards a mixing chamber by energy generated by a manual activation element that is rotated with a unidirectional twist to energise one or more energy storage bodies, energy from which is released to generate sufficient air pressure and air flow and sufficient liquid flow for a spray to be formed from the air-liquid mixture.

Abstract: Disclosed is a battery cell including an electrode, a housing, a cell interior inside the housing, a temperature sensor, and a heat-conducting part which differs from the electrode, is entirely or partially disposed inside the housing of the battery cell, and is thermally connected to the temperature sensor.

Abstract: A sole structure for an article of footwear includes a chassis and a cushioning arrangement. The chassis includes a recess formed between a first surface and a second surface facing the first surface. The cushioning arrangement includes a first cushioning element protruding from the first surface and including a first plurality of lobes and a second cushioning element protruding from the second surface and including a second plurality of lobes contacting the first plurality of lobes. At least one of the first cushioning element and the second cushioning element may include a fluid-filled bladder. A first side of each cushioning element includes a substantially planar base and a second side of each cushioning element includes the lobes formed on an opposite side from the base. The base of each cushioning element is attached to a respective one of the surfaces of the recess.

Abstract: A semiconductor device includes a semiconductor body having opposite first and second surfaces, a gate region, and an active region arranged adjacent to the gate region in a horizontal direction. A first emitter, a first base, and a second base are arranged consecutively between the second and first surfaces in a vertical direction. A front-facing emitter is arranged in the active region and extends in the vertical direction from the first surface to the second base. Short-circuit regions extend from the first surface through the front-facing emitter to the second base. The active region has, in the horizontal direction, a first edge region adjacent to the gate region, a failure region adjacent to the first edge region, and a second edge region adjacent to the failure region. An average density of the short-circuit regions in the failure region is lower than in both edge regions.

Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).

Abstract: A method, in a server, for exchanging cryptographic keys for quantum-secure communication between the server and a client. The method includes: receiving a request message for a secure communication channel from a client, including at least one quantum-secure public ephemeral key and a first secret text; decapsulating the first secret text with a decapsulation function using a quantum-secure secret static key of the server, including generating a first secret; encapsulating the quantum-secure public ephemeral key with an encapsulation function including generating a second secret text and a second shared secret; encapsulating a quantum-secure public static key of the client using the encapsulation function, including generating a third secret text and a third shared secret; generating symmetric keys using at least the first, second, and third secrets; and sending a response message to the client, including the second and third secret texts.

Abstract: A pod has an inner volume in which beverage ingredients are stored and in which a beverage is produced when water is introduced inside. The pod includes a body where water is introduced and a closing lid where the beverage is dispensed. The pod is made of a biodegradable material. The body has a three-dimensional shape. The body can be made of a multilayer material including a paper layer and a plastic sealing layer with a tensile value at break preferably between 2% and 20%. The body also can be made of a monolayer material consisting of plastic with a tensile value at break in the range between 2% and 1000%. The closing lid is flat and made of a material having a puncture resistance value between 3 N/15 mm and 10 N/15 mm for an elongation between 1.5 mm and 3 mm.

Abstract: A power semiconductor component for voltage limiting includes a rear-side base zone electrically contacted with a rear-side electrode and a front-side base zone electrically contacted with a front-side electrode. At least one switch-on structure is embedded at least into one of the rear-side base zone and the front-side base zone and is electrically contacted by the electrode contacting the embedding base zone. At least one triggering structure is provided as a breakdown structure of a first type, present between the front-side and rear-side electrodes. At least one further triggering structure is provided as a breakdown structure of a second type, present between the front-side and rear-side electrodes. The front-side and rear-side electrodes are each electrically conductively pressure-contacted by an electrically conductive contact plate at least one of which functions as a heat sink for dissipating heat generated in the semiconductor body.

Abstract: A fluid channel for a power semiconductor module includes a die carrier configured to carry a plurality of semiconductor dies on a first side, a plurality of cooling elements arranged on a second side of the die carrier opposite the first side, and a channel wall arranged opposite the second side of the die carrier and forming a cavity. The cooling elements are arranged in the cavity. The cooling elements are attached to the die carrier at attachment points. A majority of the attachment points are positioned vertically in alignment with positions of the semiconductor dies.

Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).

Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).

Abstract: A fluid channel for a power semiconductor module includes a die carrier configured to carry a plurality of semiconductor dies on a first side, a plurality of cooling elements arranged on a second side of the die carrier opposite the first side, and a channel wall arranged opposite the second side of the die carrier and forming a cavity. The cooling elements are arranged in the cavity. The cooling elements are attached to the die carrier at attachment points. A majority of the attachment points are positioned vertically in alignment with positions of the semiconductor dies.

Abstract: A high-voltage battery for a motor vehicle has at least one battery cell for storing electrical energy and at least one temperature sensor, by which a temperature of the battery cell can be detected. The temperature sensor is arranged within the battery cell.

Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).

Abstract: Disclosed is a battery cell including an electrode, a housing, a cell interior inside the housing, a temperature sensor, and a heat-conducting part which differs from the electrode, is entirely or partially disposed inside the housing of the battery cell, and is thermally connected to the temperature sensor.

Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).